Hardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement

Hardman & Co: Treatment planning system agreement

AVO's goal is to deliver a more affordable, novel, proton-based radiotherapy system, based on state-of-the-art technology developed originally at the world-renowned CERN. Major technical milestones were achieved in 2017 and the company remains on track with its development plan. Confidence has been boosted greatly by the integration of the first three structures and overcoming the technical challenge of accelerating the proton beam. With the hardware progressing well, AVO has announced a strategic collaboration with RaySearch for the development of the treatment planning system for LIGHT in Harley Street.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/advanced-oncotherapy-documents/29.08.2018-treatment-planning-system-agreement.pdf

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.